Literature DB >> 12804130

Hyperglycemia from olanzapine treatment in adolescents.

Yuval Bloch1, Osnat Vardi, Shlomo Mendlovic, Yechiel Levkovitz, Doron Gothelf, Gideon Ratzoni.   

Abstract

The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain. Of the reports of glucose dysregulation related to olanzapine therapy, only a few pertain to adolescents. We present five cases: two youths who consequently suffered from overt diabetes and three who responded with glucose dysregulation. According to the Naranjo probability scale, the relation of this phenomenon to olanzapine therapy is "probable." We consider the findings of the presented case series as justification for regular metabolic follow-up for apparently healthy adolescents receiving olanzapine therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804130     DOI: 10.1089/104454603321666234

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  7 in total

Review 1.  Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Authors:  Gabriele Masi; Francesca Liboni
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry.

Authors:  Dan Cohen; Saskia Huinink
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  Children with schizophrenia: clinical picture and pharmacological treatment.

Authors:  Gabriele Masi; Maria Mucci; Cinzia Pari
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Pharmacotherapy of pervasive developmental disorders in children and adolescents.

Authors:  Gabriele Masi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

Review 6.  Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Authors:  Kimberly A Stigler; Marc N Potenza; David J Posey; Christopher J McDougle
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.

Authors:  Sanjiv Kumra; Harvey Kranzler; Ginny Gerbino-Rosen; Hana M Kester; Courtney DeThomas; Kathyrn Cullen; James Regan; John M Kane
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-08       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.